每份预融资认股权证可行权以每股0.0001美元的行权价格购买一股有表决权的普通股。The Biotechnology company TScan Therapeutics (TCRX.US) announced on Thursday that it will sell approximately 30 million dollars in pre-financing warrants.
According to Zhituo Finance APP, biotechnology company TScan Therapeutics (TCRX.US) announced on Thursday that it will sell approximately 30 million US dollars in pre-financing warrants, allowing the purchase of up to 7.5 million shares of voting stock at a price of 4.00 US dollars per share. As of the time of reporting, the public offering was up 22.68%, quoted at 3.57 US dollars.
TCRX has signed a securities purchase agreement with Lynx1 Capital Management and the investment fund of Lynx1 Consulting.
Each pre-financing warrant can be exercised to purchase one share of voting common stock at an exercise price of 0.0001 US dollars per share.
The financing is expected to be completed around December 27.
